Article Text

Download PDFPDF
Functional, molecular and proteomic characterisation of bone marrow mesenchymal stem cells in rheumatoid arthritis
  1. M-C Kastrinaki1,
  2. P Sidiropoulos2,
  3. S Roche3,
  4. J Ringe4,
  5. S Lehmann3,
  6. H Kritikos2,
  7. V-M Vlahava1,
  8. B Delorme5,
  9. G D Eliopoulos1,
  10. C Jorgensen6,
  11. P Charbord5,
  12. T Häupl4,
  13. D T Boumpas2,
  14. H A Papadaki1
  1. 1
    Department of Haematology, University of Crete School of Medicine, Heraklion, Crete, Greece
  2. 2
    Department of Rheumatology, Clinical Immunology and Allergiology, University of Crete School of Medicine, Heraklion, Crete, Greece
  3. 3
    Institut de Génétique Humaine, UPR1142 CNRS, Montpellier, France
  4. 4
    Department of Rheumatology and Clinical Immunology, Charité Universitätsmedizin, Berlin, Germany
  5. 5
    Equipe INSERM-ESPRI/EA-3855, Faculty of Medicine, University Francois Rabelais, Tours, France
  6. 6
    Service d’Immuno-Rhumatologie, Hopital Lapeyronie, Montpellier, France
  1. H A Papadaki, University of Crete School of Medicine, P.O. Box 1352, Heraklion, Crete, Greece; epapadak{at}


Objective: Bone marrow (BM) mesenchymal stem cells (MSCs) are being considered as potential therapeutic agents in various inflammatory autoimmune diseases for their tissue-repair and anti-inflammatory tissue-protective properties. This study investigates the reserves and function, the molecular and proteomic profile and the differentiation potential of BM MSCs in patients with active rheumatoid arthritis (RA).

Methods: We evaluated the frequency of MSCs in the BM mononuclear cell fraction using a limiting dilution assay, the proliferative/clonogenic potential and the capacity of cells to differentiate towards the osteogenic/chondrogenic/adipogenic lineages using appropriate culture conditions. We also assessed the molecular and proteomic characteristics in terms of inflammatory cytokine gene and protein expression, the relative telomere length and the survival characteristics of BM MSCs.

Results: MSCs from patients with RA (n = 26) and age- and sex-matched healthy individuals (n = 21) were similar in frequency, differentiation potential, survival, immunophenotypic characteristics, and protein profile. Patient MSCs, however, had impaired clonogenic and proliferative potential in association with premature telomere length loss. Transcriptome analysis revealed differential expression of genes related to cell adhesion processes and cell cycle progression beyond the G1 phase. Previous treatment with methotrexate, corticosteroids, anti-cytokine and biological agents or other disease-modifying anti-inflammatory drugs did not correlate with the clonogenic and proliferative impairment of BM MSCs.

Conclusion: In spite of some restrictions related to the impaired clonogenic and proliferative potential, our findings support the use of autologous BM MSCs in RA and may have important implications for the ongoing efforts to repair tissue injury commonly seen in the course of the disease.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Supplementary tables 1–3 and supplementary fig 1 are published online only at

  • Funding: This study was supported by the 6th European Union Framework Program (FP6, GENOSTEM #503161).

  • Competing interests: None declared.

  • Ethics approval: The Institutional ethics committee approved the study and informed consent according to the Helsinki Declaration was obtained from all subjects.